We are live on ! Find out more
HS

HighVista Strategies Portfolio holdings

AUM $362M
1-Year Est. Return 230.96%
This Fund
S&P 500
This Quarter Est. Return
+3.78%
1 Year Est. Return
+230.96%
3 Year Est. Return
+518.4%
5 Year Est. Return
+644.94%
10 Year Est. Return
+2,223.31%
AUM
$274M
AUM Growth
-$6.67M
Cap. Flow
-$848K
Cap. Flow %
-0.31%
Top 10 Hldgs %
29.37%
Holding
164
New
33
Increased
27
Reduced
41
Closed
27

Top Buys

Rank Stock Value
1
CTLT
CATALENT, INC.
CTLT
+$4.22M
2
ETRN
Equitrans Midstream Corporation Common Stock
ETRN
+$4.16M
3
HCP
HashiCorp, Inc. Class A Common Stock
HCP
+$4.05M
4
CRM icon
Salesforce
CRM
+$2.28M
5
TEVA icon
Teva Pharmaceuticals
TEVA
+$2.1M

Top Sells

Rank Stock Value
1
SP
SP Plus Corporation
SP
+$4.12M
2
OFIX icon
Orthofix Medical
OFIX
+$2.44M
3
IDYA icon
IDEAYA Biosciences
IDYA
+$2.31M
4
IMCR icon
Immunocore
IMCR
+$2.26M
5
NUVL
Nuvalent
NUVL
+$2.23M

Sector Composition

Rank Sector Weight
1 Healthcare 43.71%
2 Technology 17%
3 Consumer Discretionary 6.54%
4 Energy 4.11%
5 Consumer Staples 3.64%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ELVN icon
26
Enliven Therapeutics
ELVN
$4.35B
$2.8M 1.02%
119,789
-7,065
-6% -$149K
XPO icon
27
XPO
XPO
$23.6B
$2.7M 0.99%
25,480
-12,900
-34% -$1.45M
OLMA icon
28
Olema Pharmaceuticals
OLMA
$1.05B
$2.68M 0.98%
247,880
– –
SYRE icon
29
Spyre Therapeutics
SYRE
$9.25B
$2.67M 0.98%
113,550
-40,831
-26% -$1.38M
VRDN icon
30
Viridian Therapeutics
VRDN
$2.59B
$2.58M 0.94%
198,484
– –
BCYC
31
Bicycle Therapeutics
BCYC
$288M
$2.58M 0.94%
127,255
-31,038
-20% -$701K
CPRI icon
32
Capri Holdings
CPRI
$1.72B
$2.57M 0.94%
77,700
– –
PCVX icon
33
Vaxcyte
PCVX
$8.73B
$2.44M 0.89%
32,313
+22,992
+247% +$1.57M
COGT icon
34
Cogent Biosciences
COGT
$7.09B
$2.37M 0.87%
281,093
– –
V icon
35
Visa
V
$671B
$2.34M 0.86%
8,927
– –
FISV
36
Fiserv Inc
FISV
$27.7B
$2.32M 0.85%
15,553
+2,900
+23% +$439K
TEVA icon
37
Teva Pharmaceuticals
TEVA
$41.1B
$2.22M 0.81%
+136,500
New +$2.1M
NUVL
38
DELISTED
Nuvalent
NUVL
$2.18M 0.8%
28,698
-31,313
-52% -$2.23M
GOOG icon
39
Alphabet (Google) Class C
GOOG
$4.31T
$2.1M 0.77%
11,436
-900
-7% -$153K
TMUS icon
40
T-Mobile US
TMUS
$189B
$2.1M 0.77%
11,900
+2,400
+25% +$402K
META icon
41
Meta Platforms (Facebook)
META
$1.51T
$2.06M 0.75%
4,090
-400
-9% -$194K
PTC icon
42
PTC
PTC
$16.6B
$1.92M 0.7%
10,581
+3,200
+43% +$573K
SWTX
43
DELISTED
SpringWorks Therapeutics
SWTX
$1.92M 0.7%
50,987
– –
MLTX icon
44
MoonLake Immunotherapeutics
MLTX
$1.45B
$1.86M 0.68%
42,249
-17,520
-29% -$742K
STX icon
45
Seagate
STX
$185B
$1.84M 0.67%
17,800
+5,000
+39% +$467K
AUTL
46
Autolus Therapeutics
AUTL
$572M
$1.81M 0.66%
518,820
+257,496
+99% +$1.11M
TVTX icon
47
Travere Therapeutics
TVTX
$5.8B
$1.8M 0.66%
219,416
– –
EQR icon
48
Equity Residential
EQR
$24.6B
$1.8M 0.66%
25,900
+4,000
+18% +$260K
KROS icon
49
Keros Therapeutics
KROS
$213M
$1.79M 0.65%
39,208
– –
WDC icon
50
Western Digital
WDC
$153B
$1.79M 0.65%
31,223
+5,028
+19% +$279K
1
2
3 4 5

Similar funds

SIAG
Safeguard Investment Advisory Group Corona, California $362M AUM 20.96% 1-Year Est. Return
MS
Millington Securities Red Bank, New Jersey $362M AUM
WI
WBI Investments Red Bank, New Jersey $362M AUM 23.75% 1-Year Est. Return
WTFG
Wood Tarver Financial Group Boise, Idaho $362M AUM 14.75% 1-Year Est. Return
VIA
Virtus Investment Advisers Hartford, Connecticut $363M AUM 34.89% 1-Year Est. Return
A6
Anchor @ 65 Singapore $362M AUM 20.02% 1-Year Est. Return
PI
Pennant Investors Summit, New Jersey $361M AUM 134.26% 1-Year Est. Return
ACM
Anfield Capital Management Irvine, California $363M AUM 24.08% 1-Year Est. Return

HighVista Strategies's Q2 2024 Portfolio in Review

As of Q2 2024, HighVista Strategies held 164 positions worth $274M, down 2.4% from $280M the previous quarter. Its ten largest holdings account for 29% of the portfolio.

HighVista Strategies's Q2 2024 filing shows 33 new, 27 increased, 41 reduced and 27 closed positions. Its largest new stake was CATALENT, INC.: 75,600 shares worth $4.25M. The largest sale was SP Plus Corporation, an estimated $4.12M.

By sector, the portfolio is most concentrated in Healthcare at 44% of assets, down from 45% a quarter earlier, followed by Technology and Consumer Discretionary.

  • HighVista Strategies's largest Q2 2024 buy was CATALENT, INC.: 75,600 shares worth $4.25M.
  • HighVista Strategies added most to Salesforce in Q2 2024, an estimated $2.28M increase.
  • HighVista Strategies's biggest Q2 2024 reduction was IDEAYA Biosciences, cutting an estimated $2.31M.
  • HighVista Strategies fully exited SP Plus Corporation in Q2 2024, selling an estimated $4.12M.
  • HighVista Strategies's ten largest holdings make up 29% of its $274M portfolio in Q2 2024.
  • HighVista Strategies opened 33 new positions and closed 27 in Q2 2024.
  • HighVista Strategies's portfolio value fell 2.4% quarter-over-quarter to $274M.

Based on HighVista Strategies's 13F filing for Q2 2024, filed 14 Aug 2024.